Table 1. Patient characteristics Patient... | American Society of Hematology

Table 1.

Patient characteristics

Patient	Age at BRT (y)	Length of follow-up (mo)	Sex	Histology	Prior ASCT	CNS prophylaxis	Prior lines of CNS therapy	HD-MTX	Interval MTX to RT (days)	CNS disease status at RT	Systemic disease status at RT	KPS at RT	CNS site involved	RT field	RT dose (cGy)	RT fractions	Concurrent systemic therapy with RT	Preparative regimen	Apheresis to infusion time (d)	CART product	Baseline ICE	ICANS	ICANS duration	CRS	CRS duration	Requiring biologics or steroids?	Best CNS response post CAR T	Best overall response post CAR T	Status at last follow up
1	60	5.7	Male	Mantle cell	No	No	4	No		PD	PD	80	Leptomeninges	Orbits	1500	10	Venetoclax	Cy/Flu	70	Liso-cel	Not available	0	0	0	0	None	CR	PD	Dead
2v	36	5.7	Female	Burkitt	Yes	Yes	2	Yes	0	PD	ND	80	Leptomeninges	Whole brain	2000	5	HD-MTX	Cy/Flu	25	Tisa-cel	Not available	1	Not available	0	0	None	CR	PR	Dead
3	74	3.3	Female	DLBCL	No	No	2	Yes	21	PD	SD	60	Leptomeninges	T11-L3	2000	5	Ibrutinib	Cy/Flu	63	Tisa-cel	5	3	25	3	2	Tocilizumab	PD	PD	Dead
4	70	10.1	Male	Mantle cell	Yes	No	0	No		N/A	PD	90	Epidural	T8 - L1	2000	5	None	Cy/Flu	81	Liso-cel	10	0	0	1	5	None	N/A	CR	Dead
5	66	33.1	Male	DLBCL	No	No	2	Yes	174	PD	ND	90	Brain parenchyma	Partial brain	3000	10	None	Cy/Flu	45	Tisa-cel	10	0	0	0	0	None	CR	PD	Alive
6	41	23.0	Female	PCNSL	Yes	No	4	Yes	62	PD	N/A	80	Brain parenchyma	Whole brain	2400	12	None	Cy/Flu	54	Tisa-cel	10	0	0	2	5	None	CR	CR	Alive
7	48	11.4	Female	DLBCL	No	No	2	Yes	179	PD	ND	50	Brain parenchyma	Whole brain	2400	12	None	Cy/Flu	69	Liso-cel	6	4	Not available	2	4	Tocilzumab, anakinra, steroids, IVIG	PR	PR	Dead
8	51	12.6	Male	DLBCL	No	No	0	No		N/A	SD	90	Epidural	C5-C7, sacrum	2000	5	None	Bendamustine	28	Axi-cel	10	0	0	2	7	Tocilizumab, steroids	N/A	PR	Alive
9	30	11.9	Female	DLBCL	Yes	No	3	Yes	46	PD	ND	90	Brain parenchyma	Partial brain	3300	11	None	Cy/Flu	61	Liso-cel	10	4	7	1	3	Tocilizumab	CR	CR	Alive
10	61	15.6	Male	DLBCL	Yes	Yes	2	Yes	393	PD	ND	80	Leptomeninges	Cauda	2000	5	Ibrutinib	Cy/Flu	199	Liso-cel	10	0	0	1	1	Tocilizumab, steroids	CR	CR	Alive
11	71	8.3	Male	DLBCL	No	No	2	Yes	32	PD	PD	60	Brain parenchyma	Partial brain	3000	10	None	Bendamustine	68	Liso-cel	10	2	15	2	6	Tocilizumab, anakinra, steroids	CR	CR	Alive
12	76	6.9	Female	DLBCL	No	No	3	Yes	9	PD	ND	90	Brain parenchyma	Partial brain	3000	10	None	Cy/Flu	129	Liso-cel	10	0	0	0	0	None	CR	CR	Alive

Patient	Age at BRT (y)	Length of follow-up (mo)	Sex	Histology	Prior ASCT	CNS prophylaxis	Prior lines of CNS therapy	HD-MTX	Interval MTX to RT (days)	CNS disease status at RT	Systemic disease status at RT	KPS at RT	CNS site involved	RT field	RT dose (cGy)	RT fractions	Concurrent systemic therapy with RT	Preparative regimen	Apheresis to infusion time (d)	CART product	Baseline ICE	ICANS	ICANS duration	CRS	CRS duration	Requiring biologics or steroids?	Best CNS response post CAR T	Best overall response post CAR T	Status at last follow up
1	60	5.7	Male	Mantle cell	No	No	4	No		PD	PD	80	Leptomeninges	Orbits	1500	10	Venetoclax	Cy/Flu	70	Liso-cel	Not available	0	0	0	0	None	CR	PD	Dead
2v	36	5.7	Female	Burkitt	Yes	Yes	2	Yes	0	PD	ND	80	Leptomeninges	Whole brain	2000	5	HD-MTX	Cy/Flu	25	Tisa-cel	Not available	1	Not available	0	0	None	CR	PR	Dead
3	74	3.3	Female	DLBCL	No	No	2	Yes	21	PD	SD	60	Leptomeninges	T11-L3	2000	5	Ibrutinib	Cy/Flu	63	Tisa-cel	5	3	25	3	2	Tocilizumab	PD	PD	Dead
4	70	10.1	Male	Mantle cell	Yes	No	0	No		N/A	PD	90	Epidural	T8 - L1	2000	5	None	Cy/Flu	81	Liso-cel	10	0	0	1	5	None	N/A	CR	Dead
5	66	33.1	Male	DLBCL	No	No	2	Yes	174	PD	ND	90	Brain parenchyma	Partial brain	3000	10	None	Cy/Flu	45	Tisa-cel	10	0	0	0	0	None	CR	PD	Alive
6	41	23.0	Female	PCNSL	Yes	No	4	Yes	62	PD	N/A	80	Brain parenchyma	Whole brain	2400	12	None	Cy/Flu	54	Tisa-cel	10	0	0	2	5	None	CR	CR	Alive
7	48	11.4	Female	DLBCL	No	No	2	Yes	179	PD	ND	50	Brain parenchyma	Whole brain	2400	12	None	Cy/Flu	69	Liso-cel	6	4	Not available	2	4	Tocilzumab, anakinra, steroids, IVIG	PR	PR	Dead
8	51	12.6	Male	DLBCL	No	No	0	No		N/A	SD	90	Epidural	C5-C7, sacrum	2000	5	None	Bendamustine	28	Axi-cel	10	0	0	2	7	Tocilizumab, steroids	N/A	PR	Alive
9	30	11.9	Female	DLBCL	Yes	No	3	Yes	46	PD	ND	90	Brain parenchyma	Partial brain	3300	11	None	Cy/Flu	61	Liso-cel	10	4	7	1	3	Tocilizumab	CR	CR	Alive
10	61	15.6	Male	DLBCL	Yes	Yes	2	Yes	393	PD	ND	80	Leptomeninges	Cauda	2000	5	Ibrutinib	Cy/Flu	199	Liso-cel	10	0	0	1	1	Tocilizumab, steroids	CR	CR	Alive
11	71	8.3	Male	DLBCL	No	No	2	Yes	32	PD	PD	60	Brain parenchyma	Partial brain	3000	10	None	Bendamustine	68	Liso-cel	10	2	15	2	6	Tocilizumab, anakinra, steroids	CR	CR	Alive
12	76	6.9	Female	DLBCL	No	No	3	Yes	9	PD	ND	90	Brain parenchyma	Partial brain	3000	10	None	Cy/Flu	129	Liso-cel	10	0	0	0	0	None	CR	CR	Alive

Summary of demographic, clinical, treatment, and toxicity characteristics for 12 patients.

ASCT, autologous stem cell transplant; Axi-cel, axicabtagene ciloleucel; cGy, centigray; Cy, cyclophosphamide; DLBCL, diffuse large B-cell lymphoma; Flu, fludarabine; IVIG, IV immunoglobulin; KPS, Karnofsky Perfomance Status; Liso-cel, Lisocabtagene maraleucel; N/A, not applicable; ND, no disease; PCNSL, primary central nervous sytem lymphoma; RT, radiotherapy; SD, stable disease; Tisa-cel, tisagenlecleucel.

View Large

This Feature Is Available To Subscribers Only